WHAT IS INTERCEPT-MDS?
EXPLORING CELL-TO-CELL HETEROGENEITY AND EXPLOITING EPIGENETIC REGULATION FOR THE INTERCEPTION OF MYELOID DISEASE CELLS
INTERCEPT-MDS is an Innovative Training Network funded by the European Union’s Horizon 2020 research and innovation programme.
Born from the LifeTime Initiative, the aim of INTERCEPT-MDS is to train Europe’s first experts at the doctorate level in the novel field of disease interception: treating a disease before it fully develops by removing altered cells.
INTERCEPT-MDS brings together 10 European public and private institutions in a European network of experts in leukaemia, epigenetics and single-cell genomics.
Through a multidisciplinary and multisectoral approach, INTERCEPT-MDS will study disease interception in the context of clonal myeloid diseases, using single-cell genomic methods to identify altered cells and test epigenetic perturbations to specifically remove them.
Image modified from Rajewsky, N. et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature (2020).
NEWS
21/10/2024
